HC Wainwright Issues Negative Outlook for Valneva Earnings

Valneva SE (NASDAQ:VALN) – Equities research analysts at HC Wainwright cut their FY2024 earnings per share estimates for shares of Valneva in a report released on Thursday, January 23rd. HC Wainwright analyst E. White now anticipates that the company will earn $0.13 per share for the year, down from their prior estimate of $0.15. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s FY2025 earnings at ($1.29) EPS and FY2026 earnings at ($1.17) EPS.

Valneva Trading Up 2.1 %

NASDAQ:VALN opened at $4.95 on Monday. The company has a market cap of $402.24 million, a PE ratio of -38.08 and a beta of 1.93. Valneva has a one year low of $3.62 and a one year high of $9.50. The firm has a 50-day moving average of $4.30 and a 200-day moving average of $5.72. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25.

Hedge Funds Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC raised its position in Valneva SE (NASDAQ:VALN) by 33.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 as of its most recent filing with the SEC. 11.39% of the stock is owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.